[en] Loss of Locus coeruleus (LC) noradrenergic (NA) neurons occurs in several neurodegenerative conditions including Alzheimer's disease (AD). In vitro and in vivo studies have shown that NA influences several features of AD disease including inflammation, neurodegeneration, and cognitive function. In the current study we tested if LC loss influenced beta amyloid (Abeta) plaque deposition. LC neuronal degeneration was induced in transgenic mice expressing mutant V717F human amyloid precursor protein (APP) by treatment with the selective neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine DSP4 (5mg/kg every 2 weeks beginning at age 3 months). At 9 months of age, when control mice show low amyloid load, DSP4-treated mice showed an approximately 5-fold increase in the average number of Abeta plaques. This was accompanied by an increase in the levels of APP C-terminal cleavage fragments. DSP4-treatment increased both microglial and astroglial activation. In vivo, DSP4-treatment decreased expression and activity of the Abeta degrading enzyme neprilysin, while in vitro NA increased phagocytosis of Abeta1-42 by microglia. These findings suggest that noradrenergic innervation from LC are needed to maintain adequate Abeta clearance, and therefore that LC degeneration could contribute to AD pathogenesis.
Disciplines :
Neurology
Author, co-author :
Kalinin, Sergey; Department of Anesthesiology, University of Illinois, & Jesse Brown Veteran's Affairs Research Division, Chicago, IL 60612, United States
Gavrilyuk, Vitaliy; Department of Anesthesiology, University of Illinois, Jesse Brown Veteran's Affairs Research Division, Chicago, IL 60612, United States
Polak, Paul E; Department of Anesthesiology, University of Illinois, Jesse Brown Veteran's Affairs Research Division, Chicago, IL 60612, United States
Vasser, Robert; Northwestern University, Chicago, IL 60611, United States
Zhao, Jie; Northwestern University, Chicago, IL 60611, United States
HENEKA, Michael ; Department of Neurology, University of Muenster, Muenster, Germany
Feinstein, Douglas L; Department of Anesthesiology, University of Illinois, Jesse Brown Veteran's Affairs Research Division, Chicago, IL 60612, United States
External co-authors :
yes
Language :
English
Title :
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease.
This work was funded in part by a VA MERIT grant (DLF), a grant from the American Alzheimer's Association (DLF) and from NIA (P01 AG021184, RV). We would like to thank Anthony Sharp for assistance with animal care, Dr. Elena Galea for assistance with histochemistry, and Dr. Cinzia Dello Russo for assistance with microglia preparation.
Bickford P.C., Mosimann W.F., Hoffer B.J., and Freedman R. Effects of the selective noradrenergic neurotoxin DSP4 on cerebellar Purkinje neuron electrophysiology. Life Sci 34 8 (1984) 731-741
Bondareff W., Mountjoy C.Q., Roth M., Rossor M.N., Iversen L.L., Reynolds G.P., et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1 4 (1987) 256-262
Caccamo A., Oddo S., Sugarman M.C., Akbari Y., and LaFerla F.M. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26 5 (2005) 645-654
Dello Russo C., Boullerne A.I., Gavrilyuk V., and Feinstein D.L. Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammat 1 1 (2004) 9
Dodart J.C., Meziane H., Mathis C., Bales K.R., Paul S.M., and Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 113 5 (1999) 982-990
Eckman E.A., and Eckman C.B. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33 Pt 5 (2005) 1101-1105
Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., Patel A., et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 7 3 (2005) 221-232
Fukami S., Watanabe K., Iwata N., Haraoka J., Lu B., Gerard N.P., et al. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res 43 1 (2002) 39-56
Galea E., Heneka M.T., Dello Russo C., and Feinstein D.L. Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol 23 4-5 (2003) 625-635
Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 6514 (1995) 523-527
Gotz J., Schild A., Hoerndli F., and Pennanen L. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 22 7 (2004) 453-465
Hama E., and Saido T.C. Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide. Med Hypotheses 65 3 (2005) 498-500
Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 5580 (2002) 353-356
Heneka M.T., Gavrilyuk V., Landreth G.E., O'Banion M.K., Weinberg G., and Feinstein D.L. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem 85 2 (2003) 387-398
Heneka M.T., Ramanathan M., Jacobs A.H., Dumitrescu-Ozimek L., Bilkei-Gorzo A., Debeir T., et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 26 5 (2006) 1343-1354
Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128 Pt 6 (2005) 1442-1453
Heneka M.T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D.L., and Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol 60 9 (2001) 906-916
Herrmann N., Lanctot K.L., and Khan L.R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 16 3 (2004) 261-276
Ho G.J., Drego R., Hakimian E., and Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 4 2 (2005) 247-256
Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96 6 (1999) 3228-3233
Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., et al. Metabolic regulation of brain Abeta by neprilysin. Science 292 5521 (2001) 1550-1552
Javierre M.Q., Pinto L.V., Lima A.O., and Sassine W.A. Immunologic phagocytosis by macrophages: effect by stimulation of alpha adrenergic receptors. Rev Bras Pesqui Med Biol 8 3-4 (1975) 271-274
Jonsson G., Hallman H., Ponzio F., and Ross S. DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)-a useful denervation tool for central and peripheral noradrenaline neurons. Eur J Pharmacol 72 2-3 (1981) 173-188
Kalinin S., Polak P.E., Madrigal J., Gavrilyuk V., Sharp V., Chauhan N., et al. Beta-amyloid dependent expression of inducible nitric oxide synthase in neurons: prevention by an a2-adrenergic receptor antagonist. Antioxidant Redox Signal 8 5-6 (2005) 873-933
Lee S.C., Zhao M.L., Hirano A., and Dickson D.W. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 58 11 (1999) 1163-1169
Lee V.M., Page C.D., Wu H.L., and Schlaepfer W.W. Monoclonal antibodies to gel-excised glial filament protein and their reactivities with other intermediate filament proteins. J Neurochem 42 1 (1984) 25-32
Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20 15 (2000) 5709-5714
Makranz C., Cohen G., Reichert F., Kodama T., and Rotshenker S. cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages. Glia 53 4 (2006) 441-448
Mann D.M. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing Dev 23 1 (1983) 73-94
Mann D.M., Yates P.O., and Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 45 2 (1982) 113-119
Mann D.M., Yates P.O., and Hawkes J. The pathology of the human locus ceruleus. Clin Neuropathol 2 1 (1983) 1-7
Marien M.R., Colpaert F.C., and Rosenquist A.C. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev 45 1 (2004) 38-78
Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20 11 (2000) 4050-4058
Ortega E., Marchena J.M., Garcia J.J., Barriga C., and Rodriguez A.B. Norepinephrine as mediator in the stimulation of phagocytosis induced by moderate exercise. Eur J Appl Physiol 93 5-6 (2005) 714-718
Palmer A.M., and DeKosky S.T. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect 91 2-3 (1993) 135-159
Pardossi-Piquard R., Petit A., Kawarai T., Sunyach C., Alves d.C., Vincent B., et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 46 4 (2005) 541-554
Ressler K.J., and Nemeroff C.B. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 6 8 (2001) 663-670
Roe M.T., Dawson D.V., Hulette C.M., Einstein G., and Crain B.J. Microglia are not exclusively associated with plaque-rich regions of the dentate gyrus in Alzheimer's disease. J Neuropathol Exp Neurol 55 3 (1996) 366-371
Ross S.B. Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br J Pharmacol 58 4 (1976) 521-527
Russo R., Borghi R., Markesbery W., Tabaton M., and Piccini A. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett 579 27 (2005) 6027-6030
Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11 4 (2005) 434-439
Sambamurti K., Kinsey R., Maloney B., Ge Y.W., and Lahiri D.K. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J 18 9 (2004) 1034-1036
Shie F.S., Breyer R.M., and Montine T.J. Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 166 4 (2005) 1163-1172
van der Velden V., Naber B.A., van der S.P., Hoogsteden H.C., and Versnel M.A. Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases. Cytokine 10 1 (1998) 55-65
Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 184 4 (1996) 1425-1433
Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23 20 (2003) 7504-7509
Zou L.B., Mouri A., Iwata N., Saido T.C., Wang D., Wang M.W., et al. Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory. J Pharmacol Exp Ther 317 1 (2006) 334-340
